Publicaciones en colaboración con investigadores/as de The Bristol-Myers Squibb Children's Hospital (9)

2024

  1. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2019

  1. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2825-2834

2018

  1. Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    OncoImmunology, Vol. 7, Núm. 1

2017

  1. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

    Cell, Vol. 171, Núm. 4, pp. 934-949.e15

2016

  1. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming

    Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005

  2. Cancer immunotherapy with immunomodulatory anti-CD137 and anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells

    Cancer Discovery, Vol. 6, Núm. 1, pp. 71-79

  3. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

    Clinical Cancer Research

2002

  1. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: Long-term results of a phase II trial

    Annals of Oncology, Vol. 13, Núm. 10, pp. 1665-1673